Myeloid cells meet CD8+ T cell exhaustion in cancer: What, why and how DOI Open Access

Yijie Zhai,

Xiaoting Liang, Mi Deng

et al.

Chinese Journal of Cancer Research, Journal Year: 2024, Volume and Issue: 36(6), P. 616 - 651

Published: Jan. 1, 2024

Exhausted T cell (Tex) is a specific state of dysfunction, in which these cells gradually lose their effector function and change phenotype during chronic antigen stimulation. The enrichment exhausted CD8+ (CD8+ Tex) the tumor microenvironment one important reasons leading to poor efficacy immunotherapy. Recent studies have reported many exhaustion. In addition cancer cells, myeloid can also contribute exhaustion via ways. this review, we discuss history concept exhaustion, dysfunction states, heterogeneity, origin, characteristics Tex. We then focus on effects Tex, including tumor-associated macrophages (TAMs), dendritic (DCs) neutrophils. Finally, systematically summarize current strategies recent advancements therapies reversing

Language: Английский

Recent advances and perspectives on the development of circular RNA cancer vaccines DOI Creative Commons
Zhaohui Gong, Wentao Hu, Chengwei Zhou

et al.

npj Vaccines, Journal Year: 2025, Volume and Issue: 10(1)

Published: March 1, 2025

Engineered circular RNAs (circRNAs) are emerging as promising platforms for RNA-based vaccines in cancer treatment. We summarize the recent advances of design, synthesis, and delivery circRNA-based vaccines, highlight applications challenges circRNA therapy. Further enhancements required areas such antigen selection, targeted delivery, multidimensional crosstalks, clinical trial assessments to advance efficacy safety cancer.

Language: Английский

Citations

2
Trial watch: anticancer vaccination with dendritic cells DOI Creative Commons
Francisca Borges, Raquel S. Laureano, Isaure Vanmeerbeek

et al.

OncoImmunology, Journal Year: 2024, Volume and Issue: 13(1)

Published: Oct. 9, 2024

Dendritic cells (DCs) are critical players at the intersection of innate and adaptive immunity, making them ideal candidates for anticancer vaccine development. DC-based immunotherapies typically involve isolating patient-derived DCs, pulsing with tumor-associated antigens (TAAs) or tumor-specific (TSAs), utilizing maturation cocktails to ensure their effective activation. These matured DCs then reinfused elicit T-cell responses. While this approach has demonstrated ability generate potent immune responses, its clinical efficacy been limited due immunosuppressive tumor microenvironment. Recent efforts have focused on enhancing immunogenicity vaccines, particularly through combination therapies T cell-targeting immunotherapies. This Trial Watch summarizes recent advances in cancer treatments, including development new preclinical strategies, discusses future potential vaccines evolving landscape immuno-oncology.

Language: Английский

Citations

4
CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors DOI Creative Commons
Asmaa Mohamed,

David Tyler Boone,

Shannon L. Ferry

et al.

Journal for ImmunoTherapy of Cancer, Journal Year: 2025, Volume and Issue: 13(2), P. e009994 - e009994

Published: Feb. 1, 2025

Background Responsiveness to chimeric antigen receptor (CAR) T cell therapy correlates with CAR expansion and persistence in vivo. Multiple strategies improve by increasing stem-like properties or sustaining activity combination therapies. Here, we describe the intrinsic ability of cells differentiate into memory cells, effect cytokine armoring, neoadjuvant CD4 depletion on tumor-specific endogenous cells. Methods TRP1-specific NKG2D alone Super2+IL-33 (S233) armoring and/or were evaluated immunocompetent B16F10 melanoma MC38 colon carcinoma models without preconditioning. We characterized precursors, establishment circulating (T CIRC ) resident RM subsets, protect against secondary tumors. Results had no primary tumor growth mice unless they combined S233 depletion. Unarmored expressed a phenotype tumor-draining lymph node differentiated lymphoid organs skin. In contrast, S233-armored exhibited an activated effector inefficiently central Combining unarmored increased Either induced activation that both synergized increase Conclusions TRP-1-specific have subsets but are non-protective improved responses limited generation. potentiated generation resulted protection rechallenge.

Language: Английский

Citations

0
Engineering cytokines for tumor-targeting and selective T cell activation DOI
Kun Peng, Yang‐Xin Fu, Yong Liang

et al.

Trends in Molecular Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
Unveiling the immunological landscape: comprehensive characterization of neoantigen-reactive immune cells in neoantigen cancer vaccines DOI Creative Commons
Weijiang Liu, Hong Su, Peng Guo

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 18, 2025

Neoantigen-based cancer vaccine therapy represents a promising precision oncology strategy that targets unique tumor-specific mutations to elicit robust immune response. This therapeutic approach is designed harness the host’s response against neoantigens eliminate cells. The efficacy of neoantigen vaccines dependents on coordinated action diverse cells, including T lymphocytes, dendritic B natural killer and macrophages. Each cell type plays distinct crucial role in recognizing, targeting, destroying malignant Understanding mechanisms governing both individual collective dynamics for success. comprehensive review systematically explores neoantigen-specific their dynamic interactions, clinical application progress, aiming unveil potential value future development treatment.

Language: Английский

Citations

0
Comprehensive assessment of computational methods for cancer immunoediting DOI Creative Commons
Shengyuan He, Shangqin Sun, Kun Liu

et al.

Cell Reports Methods, Journal Year: 2025, Volume and Issue: 5(3), P. 101006 - 101006

Published: March 1, 2025

Language: Английский

Citations

0
PD-L1/PD-1 checkpoint pathway regulates astrocyte morphogenesis and myelination during brain development DOI
Yanyan Wang, Mengtian Zhang, Tianyu Zhang

et al.

Molecular Psychiatry, Journal Year: 2025, Volume and Issue: unknown

Published: March 31, 2025

Language: Английский

Citations

0
Genetic insights into neuroblastoma: the role of immune cell features DOI
Yunfei Ma, Qiang He, Yan Su

et al.

Cytokine, Journal Year: 2025, Volume and Issue: 191, P. 156942 - 156942

Published: April 19, 2025

Language: Английский

Citations

0
Dendritic cells instruct T cell anti-tumor immunity and immunotherapy response DOI
Zhen Xiao, Jiajia Wang, Jingxing Yang

et al.

The Innovation Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 100128 - 100128

Published: Jan. 1, 2025

<p>Dendritic cells (DCs) are a heterogeneous population of antigen-presenting (APCs). They play pivotal roles in orchestrating innate and adaptive immune responses, particularly cancer. In tumor-draining lymph nodes (tdLNs), <i>de novo</i> priming occurs, where DCs present antigens to naive T cells, activating them initiating their clonal expansion. the tumor microenvironment (TME), intratumoral provide survival or co-stimulatory signals shape cell differentiation. However, scarcity dysfunctional states can greatly limit anti-tumor even be hijacked by tumor-related factors promote progression. Therefore, comprehensively understanding anti- pro-tumor activities is crucial. this review, we discuss ontogeny DC lineages emerging complexity states. Importantly, emphasize significant sustaining productive immunity. light these findings, also explore promising approaches for targeting boost immunity overcome resistance cancer immunotherapies. We propose that insights into rational design DC-based immunotherapeutic strategies against hold immense, underexploited potential.</p>

Language: Английский

Citations

0
Rôle des lymphocytes T CD4 dans la réponse immunitaire DOI Creative Commons
Hugo Roux, Olivier Lantz

médecine/sciences, Journal Year: 2025, Volume and Issue: 41(4), P. 336 - 345

Published: April 1, 2025

Les lymphocytes T CD4 orientent la réponse immunitaire et facilitent les réponses cytotoxiques humorales, tout en empêchant destruction de nos propres tissus par plus auto-réactifs. Cependant, à différence du déficit complet CD4, le apparent causé des mutations au niveau gène qui empêchent son expression, n’entraîne pas combiné sévère chez l’être humain. L’absence molécule limite nombre clones sélectionnés dans thymus sur base complexe majeur d’histocompatibilité type II, mais n’empêche l’acquisition programme propre aux auxiliaires leur permettant ainsi conserver majorité leurs capacités effectrices. Cette observation soulève nouvelles questions fonction particulier rôle intrinsèque CD4.

Citations

0